読み込み中
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
終値時点
$1.74
+$0.08 · +4.82%
時間外
$1.75
+$0.01 · +0.57%
10月9日 17:52 ET
日中の時刻はETです。市場データは遅延する場合があります。
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
日中レンジ
現在 $1.74
52週レンジ
現在 $1.74
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
42
適正価値
センチメント
52
まちまち
リスク
75
高リスク
モメンタム
31
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
日中レンジ
現在 $1.74
52週レンジ
現在 $1.74
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 89.3万 USD | 7.6万 USD | — | — | — |
| 粗利益 | 89.3万 USD | 7.6万 USD | — | — | — |
| 研究開発 | 1.14億 USD | 1.28億 USD | 1.07億 USD | 8207万 USD | 4625.5万 USD |
| 販売・一般管理 | 5177.7万 USD | 5608.4万 USD | 4481.5万 USD | 7093.7万 USD | 885.5万 USD |
| 営業費用 | 1.66億 USD | 1.84億 USD | 1.52億 USD | 1.53億 USD | 5511万 USD |
| 受取利息 | 1381.3万 USD | 1975.2万 USD | 2208.3万 USD | 598.3万 USD | 2000 USD |
| 支払利息 | 4000 USD | 9000 USD | 1.2万 USD | 21.5万 USD | — |
| 減価償却費と償却費 | 657.5万 USD | 543.2万 USD | 385.3万 USD | 303.6万 USD | 198.4万 USD |
| 営業利益 | −1.65億 USD | −1.84億 USD | −1.52億 USD | −1.53億 USD | −5511万 USD |
| 純利益 | −6898.6万 USD | −6118.6万 USD | −3546.8万 USD | −1.08億 USD | −5514.6万 USD |
会社概要が更新されました 2026年10月9日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$4.67
上昇余地（168.39%）この株式へのエクスポージャーを報告している上場投資信託です。
iShares Russell 2000 ETFIWM450.26万0.01%776.97億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF241.29万0.00%954億 USD0.05%$235+0.80%
Schwab U.S. Small-Cap ETFSCHA131.66万0.01%217.28億 USD0.03%$32.79+0.40%
iShares Russell 2000 Growth ETFIWO112.7万0.01%140.44億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO81.77万0.00%180億 USD0.06%$112.66+0.50%
Simplify Propel Opportunities ETFSURI80.3万1.07%7499.37万 USD2.82%$17.06-0.14%
iShares Micro-Cap ETFIWC56.69万0.04%13.19億 USD0.60%$183+0.11%
iShares Russell 2000 Value ETFIWN50.25万—137.55億 USD0.24%$210.87-0.04%iShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSimplify Propel Opportunities ETFSURIiShares Micro-Cap ETFIWCiShares Russell 2000 Value ETFIWNAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
